The Question NO ONE is Asking About GLP-1s - Ozempic / Mounjaro / Wegovy

GLP-1 Drugs and Disordered Eating: The Question Therapists Are Asking

The Binge Eating Therapist raises a question that has been largely absent from the GLP-1 conversation: what happens to your relationship with food when a drug takes away the urge to eat? This video comes from a therapist's perspective rather than a physician's, and that distinction matters. Most GLP-1 content focuses on the medical and metabolic outcomes. This video focuses on the psychological and behavioral ones, asking whether GLP-1 drugs actually heal a person's relationship with food or whether they just mask the problem by removing the hunger and craving signals that drove disordered eating patterns.

The therapist makes a provocative argument: for people with binge eating disorder or emotional eating patterns, GLP-1 drugs address the symptom (overeating) without addressing the root cause (the emotional, psychological, or trauma-based reasons behind the eating behavior). When the drug is removed, the underlying patterns are still there. The urges come back, often with force, and the patient has not developed any new coping strategies during the time they were on the medication. This does not mean GLP-1 drugs are bad. It means they work best when combined with therapeutic support that helps patients build a healthier relationship with food during the window of reduced cravings that the drug provides.

The Therapeutic Window Concept

One of the most useful frameworks in this video is the idea of a "therapeutic window." When you start a GLP-1 drug and the food noise quiets down, you have an opportunity. The constant battle with cravings is paused. You can think more clearly about why you eat the way you do, what triggers your overeating, and what emotional needs food has been filling. This is the window during which therapy, coaching, or structured behavioral work can be most effective. If you spend this window simply eating less without doing any internal work, you have missed the opportunity to make lasting changes.

The therapist also makes a point about identity and self-concept. Many people with long histories of disordered eating have built their identity around the struggle with food. When a drug removes that struggle, it can create a disorienting sense of not knowing who you are without the food battle. This is not something you will read in a prescribing guide, but it is a real experience that patients report. Having a therapist or support system to help navigate this identity shift can make the difference between lasting transformation and a temporary diet that ends when the prescription does.

What the Video Gets Right

The Binge Eating Therapist brings a perspective that is almost entirely missing from mainstream GLP-1 coverage. The argument that medication alone does not resolve the psychological drivers of disordered eating is well-supported by the therapy literature. The therapeutic window concept is practical and actionable. The video also correctly notes that stopping GLP-1 drugs without having addressed underlying eating patterns often leads to rapid weight regain and a sense of failure that can worsen psychological health.

What the Video Misses

The video could be more nuanced about the neuroscience. GLP-1 drugs are more than masking symptoms; they are changing brain chemistry in ways that may genuinely alter reward pathways. For some patients, the medication may provide enough neurological reset that their relationship with food truly changes at a biological level. The video leans heavily toward the "drugs do not fix psychology" argument without fully acknowledging that psychology and neurology are deeply intertwined. A more balanced take would recognize that medication and therapy are complementary tools that each address different aspects of the same problem.

Questions to Bring to Your Doctor (or Therapist)

This video makes a strong case for adding a therapist to your GLP-1 treatment team, especially if you have a history of binge eating, emotional eating, or disordered eating patterns. Ask your prescriber whether they recommend therapy alongside medication. If you already have a therapist, tell them about your GLP-1 use and ask them to help you use the reduced-craving period productively. Ask yourself honestly: when the food noise stopped, did I start doing the emotional work, or did I just eat less without changing anything else? And if you are considering stopping your GLP-1 drug, do you have a plan for managing the return of cravings?

Building New Coping Skills During the Medication Window

If the therapeutic window concept resonates with you, the next question is practical: what should you actually do during that window? The therapist suggests several approaches. First, start paying attention to when you would normally eat for emotional reasons and write down what you are feeling in those moments. This simple awareness practice builds the emotional literacy that emotional eating has been bypassing. You do not need to be perfect at identifying emotions. Just starting to notice "I would normally eat right now, and I think I feel anxious" is a meaningful first step that builds the foundation for more sophisticated emotional processing over time.

Second, experiment with alternative responses to emotional triggers. When you notice anxiety, try a 10-minute walk, a breathing exercise, journaling, calling a friend, or even just sitting with the feeling for five minutes to see what happens. Most emotional eaters have never sat with an uncomfortable emotion without trying to fix it with food, and the discovery that emotions pass on their own without intervention can be genuinely revelatory. The GLP-1 drug makes this experimentation easier because the food craving is muted, so you have more cognitive bandwidth available to try new responses instead of automatically reaching for the pantry.

Third, consider working with a therapist who specializes in eating behavior, particularly one trained in cognitive behavioral therapy or dialectical behavior therapy. These approaches have strong evidence for treating emotional eating and binge eating, and they are particularly effective when started during the GLP-1 treatment window because the reduced urgency of food cravings makes it easier to implement new behavioral strategies. A good therapist can help you identify your specific emotional eating triggers, develop personalized coping strategies, and build a maintenance plan for when the medication is eventually reduced or discontinued.

The therapist in this video makes one more point that deserves emphasis: the work you do during the medication window is the work that makes weight loss maintainable. GLP-1 drugs produce weight loss. Behavioral and emotional work produces weight maintenance. Without both components, the long-term success rate drops significantly. If you use the medication window to build new emotional processing skills, new coping mechanisms, new relationships with food, and new sources of pleasure and comfort, you are building a foundation that can support you even if your medication access changes in the future.

Finding the Right Therapist for This Work

Not every therapist is equipped to work with the specific issues that GLP-1 patients face around food and emotional eating. Look for a therapist who has experience with eating disorders or disordered eating, not only general talk therapy. Cognitive behavioral therapy for eating disorders, dialectical behavior therapy skills, and Health at Every Size-informed approaches are all frameworks that translate well to working with GLP-1 patients. Ask potential therapists whether they have worked with patients on weight loss medications and whether they understand the unique dynamics of the medication-assisted behavior change process. A therapist who pathologizes GLP-1 use or who treats weight loss medication as cheating is not going to be helpful. You need someone who can hold both realities: the medication is a legitimate medical tool and the psychological work is necessary for lasting change.

If individual therapy is not accessible or affordable, group therapy and support groups can provide some of the same benefits. Online communities of people on GLP-1 drugs who are working on their relationship with food can offer peer support and shared experience. Overeaters Anonymous and similar programs provide structured support for compulsive eating patterns. Even reading books on emotional eating and disordered eating during the medication window can be productive. The key is to be doing something intentional with the reduced-craving period rather than simply riding it passively and hoping the psychological patterns fix themselves. They rarely do without active engagement, and the medication will not do that work for you.

Who Should Watch This

This video is especially relevant for people with diagnosed binge eating disorder, emotional eating patterns, or any history of disordered eating. If you have been on a GLP-1 drug and noticed that while you are eating less, you have not really changed how you think about food, this video will resonate. It is also valuable for therapists and counselors who are working with clients on GLP-1 medications and want to understand the unique therapeutic opportunity and risk these drugs create. The video is less relevant for people using GLP-1 drugs primarily for diabetes management without significant eating behavior concerns.

The question this video raises is one that the GLP-1 industry needs to grapple with: are we treating obesity as a chronic disease that requires lifelong medication, or are we creating a window for genuine behavioral change? The answer may be both, but only if the therapeutic side gets the same attention as the pharmaceutical side.

What the Data Shows About GLP-1 Drugs and Mental Health Outcomes

The mental health effects of GLP-1 drugs are drawing increasing research attention. A 2024 population-based study in Nature Medicine analyzing data from over 200,000 patients found that semaglutide was associated with a 42% lower risk of new depression diagnosis compared to other anti-obesity medications, and a 53% lower risk of anxiety-related clinical visits. The STEP trials collected quality of life data using the Impact of Weight on Quality of Life-Lite (IWQOL-Lite) questionnaire and found statistically significant improvements in emotional well-being, self-esteem, and social functioning scores in the semaglutide group compared to placebo. The SELECT trial safety data did not identify an increase in suicidal ideation or behavior, which had been a concern raised by the European Medicines Agency in 2023. However, case reports of mood changes and suicidal thoughts have been submitted to the FDA FAERS database, with approximately 265 reports between 2018 and 2024. The FDA reviewed these reports and concluded in 2024 that the current evidence does not support a causal link between GLP-1 drugs and suicidality, but monitoring continues. For patients with pre-existing eating disorders, a 2023 commentary in the International Journal of Eating Disorders raised concerns that the appetite suppression from GLP-1 drugs could reinforce restrictive patterns in vulnerable individuals, recommending mental health screening before initiation.